By: Huffman, Nelson

S.B. No. 1827

A BILL TO BE ENTITLED

1	AN ACT
2	relating to the creation of the opioid abatement account.
3	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
4	SECTION 1. Subchapter G, Chapter 403, Government Code, is
5	amended by adding Section 403.1044 to read as follows:
6	Sec. 403.1044. OPIOID ABATEMENT ACCOUNT. (a) The opioid
7	abatement account is a dedicated account in the general revenue
8	fund.
9	(b) The account is composed of:
10	(1) money received by the state from any source
11	resulting directly or indirectly from an action by the state
12	against an opioid manufacturer, an opioid distributor, or another
13	person in the opioid industry relating to a violation of state or
14	federal law on the manufacture, marketing, distribution, or sale of
15	opioids;
16	(2) money appropriated or transferred to the account
17	by the legislature;
18	(3) gifts and grants contributed to the account; and
19	(4) earnings on the principal of the account.
20	(c) Money in the account may be appropriated only to a state
21	agency for the abatement of opiod-related harms.
22	(d) A state agency may use money appropriated to the agency
23	from the account only to:
24	(1) prevent opioid use disorder through

1

1 evidence-based education and prevention, such as school-based 2 prevention, early intervention, or health care services or programs 3 intended to reduce the risk of opioid use by school-age children; 4 (2) support efforts to prevent or reduce deaths from opioid overdoses or other opioid-related harms, including through 5 increasing the availability or distribution of naloxone or other 6 7 opioid antagonists for use by health care providers, first 8 responders, persons experiencing an opioid overdose, families, schools, community-based service providers, social workers, or 9 other members of the public; 10 11 (3) create and provide training on the treatment of 12 opioid addiction, including the treatment of opioid dependence with 13 each medication approved for that purpose by the United States Food and Drug Administration, medical detoxification, relapse 14 prevention, patient assessment, individual treatment planning, 15 counseling, recovery supports, diversion control, and other best 16 17 practices; 18 (4) provide opioid use disorder treatment for youths 19 and adults, with an emphasis on programs that provide a continuum of 20 care that includes screening and assessment for opiod use disorder 21 and co-occurring behavioral health disorders, early intervention, contingency management, cognitive behavioral therapy, case 22 23 management, relapse management, counseling services, and 24 medication-assisted treatments; 25 (5) provide access to patients suffering from opioid dependence to all medications approved by the United States Food 26

S.B. No. 1827

27 and Drug Administration for the treatment of opioid dependence and

2

S.B. No. 1827

1	relapse prevention following opioid detoxification, including
2	opioid agonists, partial agonists, and antagonists; and
3	(6) support treatment alternatives that provide both
4	psychosocial support and medication-assisted treatments in areas
5	with geographical or transportation-related challenges, including
6	providing access to mobile health services, and telemedicine,
7	particularly in rural areas.
8	SECTION 2. This Act takes effect September 1, 2021.

3